The Lancet Haematology

1. Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China

   Publication date: December 2022

   Source: The Lancet Haematology, Volume 9, Issue 12

   Author(s): Xiaolei Li, Hanren Dai, Yao Wang, Zhiqiang Wu, Hua Wang, Wenbin Qian, Aibin Liang, Weidong Han

2. CAR T-cell therapies in China: rapid evolution and a bright future

   Publication date: December 2022

   Source: The Lancet Haematology, Volume 9, Issue 12

   Author(s): Yongxian Hu, Jingjing Feng, Tianning Gu, Linqin Wang, Yiyun Wang, Linghui Zhou, Ruimin Hong, Elaine Tan Su Yin, Mingming Zhang, Peihua Lu, He Huang

3. Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions

   Publication date: December 2022

   Source: The Lancet Haematology, Volume 9, Issue 12

   Author(s): Ying-Jun Chang, Xu-Ying Pei, Xiao-Jun Huang

4. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis

   Publication date: December 2022

   Source: The Lancet Haematology, Volume 9, Issue 12

   Author(s): Kainat Saleem, Joseph Franz, Mary Lou Klem, Jonathan G Yabes, Michael Boyiadzis, John R Jones, Nader Shaikh, Konstantinos Lontos

5. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study

   Publication date: December 2022

   Source: The Lancet Haematology, Volume 9, Issue 12

   Author(s): Thomas Martin, Yi Lin, Mounzer Agha, Adam D Cohen, Myo Htut, A Keith Stewart, Parameswaran Hari, Jesus G Berdeja, Saad Z Usmani, Tzu-Min Yeh, Yunsi Olyslager, Jenna D Goldberg, Jordan M Schecter, Deepu Madduri, Carolyn C Jackson, William Deraedt, Katharine S Gries, John M Fastenau, Jeremiah J Trudeau, Muhammad Akram

6. 25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial

   Publication date: December 2022

   Source: The Lancet Haematology, Volume 9, Issue 12

   Author(s): Jean-Philippe Galanaud, Céline Genty-Vermorel, Marie-Thérèse Barrellier, François Becker, Violaine Jabbour, Sophie Blaise, Alessandra Bura-Rivière, Alexa Comte, Claire Grange, Herve Guenneguez, Mario Maufus, Pierre Ouvry, Cécile Richaud, Carole Rolland, Jeannot Schmidt, Marie-Antoinette Sevestre, François Verrière, Jean-Luc Bosson, Jean-Luc Bosson, Olivier Pichot

7. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial

   Publication date: December 2022

   Source: The Lancet Haematology, Volume 9, Issue 12

   Author(s): Elias Jabbour, Nicholas J Short, Nitin Jain, Philip A Thompson, Tapan M Kadia, Alessandra Ferrajoli, Xuelin Huang, Musa Yilmaz, Yesid Alvarado, Keyur P Patel, Guillermo Garcia-Manero, Walid Macaron, Rebecca Garris, Marina Konopleva, Farhad Ravandi, Hagop Kantarjian

8. COP27 Climate Change Conference: urgent action needed for Africa and the world

   Publication date: December 2022

   Source: The Lancet Haematology, Volume 9, Issue 12

   Author(s): Lukoye Atwoli, Gregory E Erhabor, Aiah A Gbakima, Abraham Haileamlak, Jean-Marie Kayembe Ntumba, James Kigera, Laurie Laybourn-Langton, Robert Mash, Joy Muhia, Fhumulani Mavis Mulaudzi, David Ofori-Adjei, Friday Okonofua, Arash Rashidian, Maha El-Adawy, Siaka Sidibé, Abdelmadjid Snouber, James Tumwine, Mohammad Sahar Yassien, Paul Yonga, Lilia Zakhama

9. Gene therapy in China: past, present, and future

   Publication date: December 2022

   Source: The Lancet Haematology, Volume 9, Issue 12

   Author(s): Lei Zhang

10. Lenalidomide and risk of second primary malignancy—is disease context key?

    Publication date: December 2022

    Source: The Lancet Haematology, Volume 9, Issue 12

    Author(s): Charlotte Pawlyn, Sarah Bird

11. Patient-reported outcomes: important data in early trials of novel therapies

    Publication date: December 2022

    Source: The Lancet Haematology, Volume 9, Issue 12

    Author(s): Heather Jim, Laura Oswald

12. Lower strength stockings: is less better?

    Publication date: December 2022

    Source: The Lancet Haematology, Volume 9, Issue 12

    Author(s): Arina J ten Cate-Hoek

13. Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia

    Publication date: December 2022

    Source: The Lancet Haematology, Volume 9, Issue 12

    Author(s): Andrés Gómez-De León, Juan Manuel Mejía-Aranguré

14. Increasing availability of oral therapy in haematology

    Publication date: December 2022

    Source: The Lancet Haematology, Volume 9, Issue 12

    Author(s): The Lancet Haematology

15. On the basis of sex: outcomes in myelodysplastic syndromes

    Publication date: Available online 24 November 2022

    Source: The Lancet Haematology

    Author(s): Michael J Hochman, Amy E DeZern

16. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study

    Publication date: Available online 24 November 2022

    Source: The Lancet Haematology

    Author(s): Giulia Maggioni, Matteo Bersanelli, Erica Travaglino, Ana Alfonso Piérola, Annika Kasprzak, Arnan Sangerman Montserrat, Elisabetta Sauta, Claudia Sala, Tommaso Matteuzzi, Manja Meggendorfer, Matteo Gnocchi, Lin-Pierre Zhao, Cristina Astrid Tentori, Kathrin Nachtkamp, Daniele Dall'Olio, Ettore Mosca, Marta Ubezio, Alessia Campagna, Antonio Russo, Giulia Rivoli

17. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

    Publication date: Available online 17 November 2022

    Source: The Lancet Haematology

    Author(s): Alex F Herrera, Lu Chen, Yago Nieto, Leona Holmberg, Patrick Johnston, Matthew Mei, Leslie Popplewell, Saro Armenian, Thai Cao, Leonardo Farol, Firoozeh Sahebi, Ricardo Spielberger, Robert Chen, Auayporn Nademanee, Sandrine Puverel, Mary Nwangwu, Peter Lee, Joo Song, Alan Skarbnik, Neena Kennedy

18. How does zanubrutinib fare in treatment of B-cell malignancies?

    Publication date: Available online 16 November 2022

    Source: The Lancet Haematology

    Author(s): D'Sa Shirley

19. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

    Publication date: Available online 16 November 2022

    Source: The Lancet Haematology

    Author(s): Elias Jabbour, Nicholas J Short, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Pinaki Banerjee, Katayoun Rezvani, Xianli Jiang, Kun Hee Kim, Rashmi Kanagal-Shamanna, Joseph D Khoury, Keyur Patel, Tapan M Kadia, Naval Daver, Kelly Chien, Yesid Alvarado, Guillermo Garcia-Manero, Ghayas C Issa, Fadi G Haddad, Monica Kwari

20. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study

    Publication date: Available online 16 November 2022

    Source: The Lancet Haematology

    Author(s): Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke, Syed F Zafar, Jamal Misleh, Edwin C Kingsley, Habte A Yimer, Benjamin Freeman, Subramanya S Rao, Arvind Chaudhry, Praveen K Tumula, Mitul D Gandhi, Sudhir Manda, Dih-Yih Chen, Kunthel By, Linlin Xu, Ye Liu, Rocco Crescenzo

21. Towards chemotherapy-free treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia

    Publication date: Available online 16 November 2022

    Source: The Lancet Haematology

    Author(s): Judith M Boer, Inge M van der Sluis

22. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

    Publication date: Available online 10 November 2022

    Source: The Lancet Haematology

    Author(s): Justin M Watts, Maria R Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J Schiller, Shira N Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S Wang, Karen P Seiter, Andrew H Wei, Stephane De Botton, Montserrat Arnan, Will Donnellan, Anthony P Schwarer, Christian Récher, Brian A Jonas, P Brent Ferrell, Christophe Marzac

23. Isolated IgG4-related disease of the left maxillary antrum

    Publication date: November 2022

    Source: The Lancet Haematology, Volume 9, Issue 11

    Author(s): Pratibha Ramani, Deepak Pandiar, Gheena Sukumaran, Suvarna Kizhakkoottu, Reshma Poothakulath Krishnan

24. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA

    Publication date: November 2022

    Source: The Lancet Haematology, Volume 9, Issue 11

    Author(s): Hagop Kantarjian, Shilpa Paul, Jigar Thakkar, Elias Jabbour

25. Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study

    Publication date: November 2022

    Source: The Lancet Haematology, Volume 9, Issue 11

    Author(s): Thijs W de Vos, Dian Winkelhorst, Valgerdur Árnadóttir, Johanna G van der Bom, Carme Canals Surís, Camila Caram-Deelder, Emöke Deschmann, Helen E Haysom, Hem Birgit C Hverven, Jana Lozar Krivec, Zoe K McQuilten, Eduardo Muñiz-Diaz, Núria Nogués, Dick Oepkes, Leendert Porcelijn, C Ellen van der Schoot, Matthew Saxonhouse, Martha Sola-Visner, Eleonor Tiblad, Heidi Tiller

26. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

    Publication date: November 2022

    Source: The Lancet Haematology, Volume 9, Issue 11

    Author(s): Reuben Benjamin, Nitin Jain, Marcela V Maus, Nicolas Boissel, Charlotte Graham, Agnieszka Jozwik, Deborah Yallop, Marina Konopleva, Matthew J Frigault, Takanori Teshima, Koji Kato, Floriane Boucaud, Svetlana Balandraud, Athos Gianella-Borradori, Florence Binlich, Ibtissam Marchiq, Sandra Dupouy, Maria Almena-Carrasco, Matthieu Pannaux, Sylvain Fouliard

27. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

    Publication date: November 2022

    Source: The Lancet Haematology, Volume 9, Issue 11

    Author(s): Sagar Lonial, Rakesh Popat, Cyrille Hulin, Sundar Jagannath, Albert Oriol, Paul G Richardson, Thierry Facon, Katja Weisel, Jeremy T Larsen, Monique C Minnema, Al-Ola Abdallah, Ashraf Z Badros, Stefan Knop, Edward A Stadtmauer, Yiming Cheng, Michael Amatangelo, Min Chen, Tuong Vi Nguyen, Alpesh Amin, Teresa Peluso

28. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

    Publication date: November 2022

    Source: The Lancet Haematology, Volume 9, Issue 11

    Author(s): Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, Roland Fenk, Eva Nievergall, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Anne M Asemissen, Bernhard Heilmeier, Niels Weinhold, Stefanie Huhn, Katharina Kriegsmann, Steffen P Luntz, Tobias A W Holderried, Karolin Trautmann-Grill

29. Blueprint for greater security of immunoglobulins for patients in Canada

    Publication date: November 2022

    Source: The Lancet Haematology, Volume 9, Issue 11

    Author(s): Graham D Sher

30. Prioritising health equity alongside donation safety – Authors' reply

    Publication date: November 2022

    Source: The Lancet Haematology, Volume 9, Issue 11

    Author(s): Mickey B C Koh, Jörg P Halter, Hildegard T Greinix, Mahmoud Aljurf, Nina Worel